TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Nursing home clinicians report that GLP-1 medications are becoming more common among residents, with use extending beyond diabetes and weight loss. Operators say the drugs may benefit some residents but require closer nutritional and clinical monitoring, while coverage rules and facility costs remain unresolved.
GLP-1 medications are appearing more often among nursing home residents, according to clinicians and operators cited by Skilled Nursing News, prompting facilities to adjust monitoring and staff education as they weigh possible health benefits against risks for frail older adults and unresolved payment questions. At one operator, 30% to 40% of new admissions are taking the drugs, its chief nursing officer said.
Lisa Chubb, chief nursing officer for New Jersey-based Venza Care, said clinicians are seeing GLP-1 prescriptions used for purposes beyond diabetes and weight loss, including cardiovascular health, metabolic conditions and other chronic diseases. The share of new admissions taking the medications is higher at facilities with more short-stay residents, she said. The figures are specific to Venza and do not establish a nationwide rate.
Chubb said weighing potential benefits against risks involves considering residents’ preferences as well as possible muscle weakness, frailty and weight loss. Venza holds weekly “nutrition at risk” meetings, uses electronic health record assessments to document medication review and education, and involves registered dietitians in monitoring residents taking GLP-1s.
Payment varies by coverage and the circumstances of a resident’s stay. Jessie McGill of the American Association for Post-Acute Care Nursing (AAPACN) said a Medicare Part D bridge program covers certain drugs for weight loss, subject to eligibility, with a $50 monthly fee in addition to Part D coverage. The eligible medications named in the report are Wegovy, Zepbound and Foundeo. A more permanent program, BALANCE, has been delayed without a future implementation date; the bridge program has been extended through 2027.
Care Plans Meet Medication Costs
The increase affects both clinical routines and facility budgets. Nursing home residents may have several chronic conditions, nutritional concerns or limited functional ability, so a treatment linked to weight loss cannot be evaluated by weight change alone. Facilities may need to track nutrition, hydration and side effects while coordinating decisions among nursing staff, prescribers, dietitians and residents.
The financial rules can also shape whether a facility can continue a prescription after admission. McGill said residents receiving Medicare Part A may leave the nursing home responsible for a GLP-1’s cost. For drugs outside the bridge program, that expense can be significant for an operator. Jody O’Mara, chief nursing officer for Journey Skilled Nursing, said her company views potential benefits as outweighing costs, but that view does not resolve how other facilities or residents will pay.
The issue matters to residents and families because coverage eligibility, monthly fees and medication choices may affect access. It also matters to operators planning pharmacy services and care assessments. The report does not provide comparative clinical outcomes or national cost estimates, so the broader effects on resident health and facility spending remain uncertain.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
Medicare Coverage Still in Flux
The report describes a temporary Medicare Part D bridge arrangement for some residents seeking GLP-1 treatment for weight loss. McGill said it applies to eligible residents who have not already been prescribed a GLP-1 for diabetes, which is covered under Part D. Eligibility also depends on criteria involving body mass index and other chronic conditions, according to her account.
Coverage is not the same for every resident or medication. McGill said people who are dually eligible for Medicare and Medicaid may still struggle to pay the $50 monthly fee. If a resident is on Medicare Part A and the prescribed medication is not covered through the bridge program, the facility may face the cost. McGill said one possible policy change would be for Congress to expand consolidated billing to include high-cost drugs such as GLP-1s; the report does not indicate that Congress has acted.
“We see a lot of our new admissions coming in with GLP-1s. Initially it was used solely for weight loss and diabetes, but now we’re seeing it trend in other directions as well.”
— Lisa Chubb, chief nursing officer for Venza Care
Outcomes and Coverage Gaps
The report does not establish how widespread GLP-1 use is across nursing homes nationally, whether the increase is producing better health outcomes for this population, or how frequently treatment leads to complications. Venza’s admission figures are an operator-specific estimate, not a national survey.
It is also unclear when or whether BALANCE will be implemented, which residents will qualify under future rules, and how facilities will handle costs for medications outside the bridge program. The source material does not detail the clinical evidence for each use described by providers, nor does it provide a full account of prescribing decisions or resident outcomes.
Bridge Program Runs Through 2027
The Medicare bridge program is scheduled to continue through 2027, according to the report. No future implementation date has been announced for BALANCE. Facilities will need to work within existing coverage rules while assessing medication costs, resident eligibility and clinical monitoring needs.
Providers cited in the report expect GLP-1s to affect facility assessments, pharmacy arrangements and quality-improvement work. McGill identified congressional action on consolidated billing as a possible route to address some high-cost medication expenses, but any change remains a proposal rather than an enacted policy. The next material developments will be updates to federal coverage and evidence on how these drugs affect older nursing home residents.
Key Questions
How common are GLP-1 medications among nursing home residents?
Venza Care’s Lisa Chubb said 30% to 40% of new admissions at her operator are taking GLP-1s, with a higher share at facilities with more short-stay residents. That is an operator-specific figure, not a national estimate.
Does Medicare cover GLP-1 drugs for weight loss?
The report says a Medicare Part D bridge program covers certain GLP-1s for eligible residents seeking treatment for weight loss, subject to criteria and a $50 monthly fee in addition to Part D coverage. The report names Wegovy, Zepbound and Foundeo as eligible medications.
Who may pay for a resident’s GLP-1 in a nursing home?
Payment depends on the resident’s coverage, the medication and eligibility for the bridge program. AAPACN’s Jessie McGill said a facility may be responsible for the medication cost for residents on Medicare Part A, particularly when the drug is not included in the bridge program.
Why do clinicians have concerns about GLP-1 use in nursing homes?
Clinicians cited in the report say some residents are already frail or have nutritional and functional limitations. Potential concerns include muscle weakness, weight loss, nausea, vomiting, constipation and dehydration; the report does not say these effects occur in every resident.
When will the permanent coverage program begin?
The report says the proposed permanent program, called BALANCE, was delayed and has no future implementation date. The temporary bridge program has been extended through 2027.
Source: skillednursingnews.com
